The 2025 EULAR recommendations for rheumatoid arthritis confirm that treat-to-target strategies, early escalation and personalised risk assessment remain the cornerstones of modern RA management. Methotrexate continues as the anchor therapy, and clinical remission is an achievable goal for the majority of patients diagnosed and treated promptly.
- Methotrexate remains the recommended first-line DMARD for most patients with RA, with early escalation when disease control is inadequate after 3–6 months
- Treat-to-Target (T2T) — aiming for clinical remission or low disease activity — is the established standard of care in modern rheumatology
- JAK inhibitors require careful, individualised assessment of cardiovascular, thrombotic and malignancy risk before prescribing
- Sustained remission may allow cautious tapering, but complete discontinuation frequently leads to relapse and is not recommended for most patients
What the 2025 EULAR Update Means for Patients
The European Alliance of Associations for Rheumatology (EULAR) has published its latest guidance for the management of rheumatoid arthritis, updating the 2022 framework in light of growing evidence on treatment sequencing, biologic safety, JAK inhibitor risk stratification and long-term outcomes.
Rheumatoid arthritis is a systemic autoimmune condition in which the immune system attacks the synovial lining of the joints, causing chronic inflammation, pain, swelling and — without adequate treatment — progressive joint destruction. In the UK, approximately 400,000 people live with RA, and the condition affects women approximately three times more frequently than men [1].
The 2025 update provides greater clarity around treatment pathways and reaffirms a message that has consistently driven better outcomes in RA care: treat early, treat effectively, monitor closely and aim for remission. While the therapeutic landscape for RA has never been stronger, the challenge is not whether effective therapies exist — it is identifying the right treatment for the right patient at the right time.
Methotrexate Remains the Foundation
Despite decades of pharmacological innovation, methotrexate remains the recommended first-line disease-modifying antirheumatic drug (DMARD) for most patients with newly diagnosed RA. This recommendation has not changed — and for good reason. Methotrexate has an unmatched evidence base accumulated over 40 years, a well-understood safety profile, and achieves meaningful disease control in a substantial proportion of patients when used optimally.
EULAR continues to recommend optimised methotrexate dosing, folic acid supplementation to reduce gastrointestinal and haematological side effects, and early escalation when clinical response is insufficient. Short-term glucocorticoids may still be used as a bridging strategy whilst DMARDs take effect, but prolonged steroid exposure should be avoided wherever possible due to well-established risks including bone loss, infection susceptibility and metabolic complications.
Patients with new RA diagnoses can be reassured that methotrexate, when properly optimised, controls disease activity effectively in many cases. Where it does not, highly effective options are available and should be initiated without delay.
Treat-to-Target: The Strategic Backbone of Modern RA Care
One of the most important principles in modern rheumatology is the Treat-to-Target (T2T) strategy, which remains central to the 2025 EULAR recommendations.
Rather than simply managing symptoms reactively, T2T requires that treatment is proactively adjusted until a predefined clinical target is achieved. For most patients, the target is clinical remission; where remission cannot be attained, low disease activity is an acceptable alternative. Disease activity is measured using validated composite scores such as the DAS28 and CDAI, typically every 1–3 months until the target is achieved, and every 3–6 months thereafter.
Historically, RA was managed on the basis of symptom burden alone. The widespread adoption of treat-to-target strategies over the past two decades has transformed patient outcomes, reducing rates of joint destruction, disability and long-term functional impairment compared with earlier management models.
Earlier Escalation to Advanced Therapies
When methotrexate-based treatment fails to achieve adequate disease control, EULAR recommends escalation at approximately 3–6 months. The updated guidance supports this transition and identifies two main classes of advanced therapy.
Biologic DMARDs
Biologic agents including TNF inhibitors, abatacept, rituximab, tocilizumab and sarilumab represent the most established second-line options. These agents target specific components of the immune response and have transformed outcomes for many patients who do not respond to conventional therapy. Their efficacy across different mechanisms of action is broadly comparable at a population level, though individual responses vary.
Targeted Synthetic DMARDs (JAK Inhibitors)
Janus kinase (JAK) inhibitors — including tofacitinib, baricitinib, filgotinib and upadacitinib — are orally administered targeted therapies that have shown comparable efficacy to biologic agents in clinical trials. They offer the convenience of oral dosing and act more rapidly than some injectable biologics. However, post-marketing safety data have added important nuance to their use.
A More Nuanced View of JAK Inhibitor Safety
Perhaps the most significant discussion in the 2025 update concerns the safety profile of JAK inhibitors. Following the ORAL Surveillance study and subsequent regulatory reviews, concerns have emerged regarding elevated risks of major adverse cardiovascular events (MACE), venous thromboembolism and certain malignancies in higher-risk patient groups [2].
The updated recommendations therefore emphasise individualised risk assessment before prescribing JAK inhibitors. Clinicians should carefully consider each patient’s:
- Age (risk increases significantly over 65)
- Smoking history
- Pre-existing cardiovascular risk factors
- History of venous thromboembolism
- Personal or family history of malignancy
For patients without significant risk factors, JAK inhibitors remain highly effective and appropriate options. For those with elevated risk, biologic DMARDs with a more established long-term safety profile may be preferred. Crucially, treatment decisions should be made collaboratively — with patients fully informed of relevant risks and benefits — rather than being protocol-driven [3].
What If the First Advanced Therapy Fails?
The recommendations reinforce an important practical point: failure of one biologic does not mean failure of all biologics. If the first biologic or JAK inhibitor is ineffective or not tolerated, switching to a different agent within the same class, or to a different mechanism of action entirely, is clinically appropriate and often successful.
This flexibility reflects real-world clinical practice and is reassuring for patients who have experienced treatment failure. A thorough review with a specialist rheumatologist helps identify the most appropriate next step, taking into account disease activity, comorbidities and patient preference.
Can Treatment Be Reduced in Remission?
One of the most frequent questions we hear from patients: “If I reach remission, can I reduce or stop my medication?”
The 2025 EULAR guidance supports cautious tapering in patients with sustained, stable remission — but advises strongly against abrupt discontinuation. The evidence consistently shows that complete cessation of therapy leads to relapse in the majority of patients, even after prolonged remission. The goal of tapering is therefore dose optimisation, not treatment withdrawal. Any reduction should be carried out gradually, with close monitoring, and treatment should be restored promptly if disease activity resurfaces.
The Next Frontier: Precision Medicine in RA
A fascinating and clinically important observation in the 2025 update is that most targeted therapies appear similarly effective when analysed across large patient groups — yet individual responses vary enormously. One patient may respond dramatically to a TNF inhibitor; another may fail several agents before finding the right therapy.
The next frontier in rheumatology is therefore not simply developing more drugs — it is developing better tools to predict who will respond, which mechanism will work best, when escalation should occur, and who may safely taper treatment. Biomarker research and machine learning approaches are now active areas of investigation, with the goal of making precision medicine in RA a clinical reality.
RA and Bone Health: A Connection That Must Not Be Overlooked
One consideration that deserves particular attention in RA management is bone health. Chronic inflammation in RA accelerates bone resorption, and long-term glucocorticoid use — often necessary during the early phases of treatment — compounds this risk further. Patients with RA have a significantly elevated risk of osteoporosis and fragility fractures compared with the general population.
At the London Osteoporosis Clinic, we assess bone density in patients with RA as part of a comprehensive rheumatological review. The link between inflammatory arthritis and osteoporosis is well established, and proactive DEXA scanning allows us to identify and treat bone loss before it leads to fracture. Diet also plays an important role — patients often ask about foods that may worsen inflammation, and we discuss this as part of a holistic management approach. Where relevant, we also consider the impact of bone-modifying agents on joint erosion alongside systemic bone density.
We often see patients who have been on methotrexate for several years and are doing well — and others who have been hesitant to escalate when the clinical picture clearly supports it. The 2025 EULAR update reinforces something we emphasise in every consultation: the goal is remission, not merely symptom control. For patients with active disease after 3–6 months of optimised methotrexate, the window for escalation is now — waiting costs the joint. With regard to JAK inhibitors, we take an individualised approach. These are effective therapies in the right patient, but patient selection matters more than ever. We review cardiovascular history, thrombotic risk and malignancy history carefully before recommending them, and we make those decisions jointly with the patient. Equally, we never lose sight of bone health — RA and the steroids often used alongside it are significant drivers of osteoporosis, and that risk needs active management from the outset.
Frequently Asked Questions
Is methotrexate still the best first treatment for rheumatoid arthritis in 2025?
Yes. The 2025 EULAR recommendations reaffirm methotrexate as the recommended first-line DMARD for the majority of patients with newly diagnosed RA. It has decades of evidence supporting its efficacy and safety, and when optimised — with appropriate dosing and folic acid supplementation — it achieves meaningful disease control in many patients. The key principle is that if methotrexate does not achieve the treatment target within 3–6 months, escalation to a biologic or targeted synthetic DMARD should follow promptly rather than persisting with inadequate control.
Are JAK inhibitors safe for rheumatoid arthritis?
JAK inhibitors are effective treatments for RA but require careful risk assessment before prescribing. The ORAL Surveillance study identified elevated risks of cardiovascular events, venous thromboembolism and certain malignancies in older patients and those with existing cardiovascular risk factors. The 2025 EULAR guidance recommends that JAK inhibitors should only be prescribed after a thorough review of each patient’s individual risk profile. For patients without significant risk factors, they remain an appropriate and highly effective option. Your rheumatologist should discuss the benefits and risks with you in detail before starting treatment.
Can I stop my rheumatoid arthritis medication if I go into remission?
Complete discontinuation is generally not recommended, even in sustained remission. The evidence consistently shows that stopping treatment — even after a prolonged period of remission — leads to relapse in the majority of patients. However, cautious tapering (gradually reducing the dose) is supported by the EULAR recommendations for patients who have achieved stable, sustained remission. The goal is dose optimisation — finding the minimum effective dose — rather than full withdrawal. Any changes to your medication regimen should be made in close collaboration with your rheumatologist, with regular monitoring of disease activity to detect early signs of flare.
Medically reviewed by Dr. Taher Mahmud, Consultant Rheumatologist and Co-Founder, London Osteoporosis Clinic. Dr. Mahmud has over 25 years of clinical experience in bone health and osteoporosis management.
This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional regarding any health concerns or before making changes to your treatment plan.
